Suppression of Myocardial Injury Markers following Percutaneous Coronary Interventions by Pre-treatment with Carvedilol

Abdolrasoul  Moloudi; Feridoun  Sabzi; Shirin  Rashidi

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Suppression of Myocardial Injury Markers following Percutaneous Coronary Interventions by Pre-treatment with Carvedilol

Author(s):

Abdolrasoul Moloudi^1,*,

Feridoun Sabzi¹,

Shirin Rashidi¹

1Emam Ali Cardiovascular Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

International Cardiovascular Research Journal:Vol. 6, issue 3; e12805

Published online:Sep 30, 2012

Article type:Research Article

Received:May 16, 2017

Accepted:Jul 09, 2012

How to Cite:Abdolrasoul MoloudiFeridoun SabziShirin RashidiSuppression of Myocardial Injury Markers following Percutaneous Coronary Interventions by Pre-treatment with Carvedilol.Int Cardiovasc Res J.2012;6(3):e12805.

Abstract

Background: Retrospective studies and clinical trials have indicated that β-receptor blockers have an influential role in improving survival and reducing risk of recurrent infarction in patients with myocardial infarction. However, there is still controversy regarding the effects of β-receptor blockers on the markers of myocardial infarction following percutaneous coronary interventions (PCI).

Objective: The aim of this study was to evaluate the pre-treatment effect of Carvedilol on markers of myocardial injury in patients undergoing elective PCI.

Method and Materials: In this clinical trial patients undergoing elective PCI were categorized randomly in the Carvedilol group including 100 patients who received two doses of 12.5 mg, 6 and 12 hours prior to PCI, and the control group (105 patients). Blood samples were obtained to analyse cardiac biomarker, 12 and 24 hours after PCI.

Results: The clinical features were not significantly different between the two groups. A increase in the level of Troponin I was observed in the control group 24 hours following PCI (P=0.042), whereas this rise in troponin I was slight and insignificant in the Carvedilol group (P>0.05). some difference was observed between the two groups in regard to the level of CPK-MB after PCI (P=0.041).

Conclusion: The findings of our study indicate that pre-treatment with Carvedilol confers cardio-protection by limiting the rise of markers of myocardial injury following PCI.

Keywords

Carvedilol

Troponin I

CPK-MB

Coronary Interventions

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

comments